$PRPH News

ProPhase Labs Reports Year-End 2025 Results, Highlights Accelerating Settlement Activity and Investment-Ready Crown Medical Collections Platform

ProPhase Labs Provides Business Update Highlighting Advancing Crown Medical Collections Activity

ABL Diagnostics Update Regarding Non-Binding Letter of Intent

ProPhase Labs Initiates Potential Sale or Strategic Partnership of BE-Smart™ and Advances Crown Medical Collections Initiative

Join ProPhase Labs’ Exclusive Live Investor Webinar and Q&A Session on February 3rd

ProPhase Labs Provides Crown Medical Collections Update; 250+ Insurance Payors Engaged, Approximately 50 Matters in Advanced Settlement Posture

ProPhase Labs Uplists from Pink Sheets to OTC Market

ProPhase Labs Provides Update on Convertible Debt Conversions, Capital Structure, and Underlying Asset Value

ProPhase Labs Says Stock Volatility Tied to Debt Conversions, Not Business Fundamentals

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

ProPhase Labs, Advanced Biological Laboratories Sign Letter of Intent for Reverse Merger

ProPhase Labs Signs Non-Binding LOI for Proposed Reverse Merger with Advanced Biological Laboratories

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

ProPhase Labs Signs Non-Binding LOI For Proposed Reverse Merger With Advanced Biological Laboratories, With ABL Expected To Own About 76% And ProPhase Considering Up To $10M Special Dividend

Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending

ABL Diagnostics Informs the Market of a Non‑Binding Letter of Intent Between ABL S.A. and ProPhase Labs (Nasdaq: PRPH) for a Proposed Reverse Merger

ProPhase Labs Approves 1-For-10 Reverse Stock Split, Effective December 22, 2025

ProPhase Labs, Inc. (PRPH) Discusses Milestones in Cancer Diagnostics, Genomics Expansion, and COVID Accounts Receivable Collection Transcript